Higher Atazanavir Plasma Exposure in Rats is Associated with Gut Microbiota Changes Induced by Cotrimoxazole.


Journal

Current drug metabolism
ISSN: 1875-5453
Titre abrégé: Curr Drug Metab
Pays: Netherlands
ID NLM: 100960533

Informations de publication

Date de publication:
2019
Historique:
received: 10 08 2019
revised: 02 10 2019
accepted: 16 10 2019
pubmed: 9 11 2019
medline: 13 5 2020
entrez: 9 11 2019
Statut: ppublish

Résumé

Cotrimoxazole (TMP-SMX) is concomitantly used as a primary prophylaxis of opportunistic infections with antiretroviral agents, such as Atazanavir (ATV). Results from an ex vivo study showed changes in intestinal absorption of ATV when rats were pretreated with TMP-SMX. The objective of this in vivo study is to determine the effect of TMP-SMX on the pharmacokinetics of ATV in rats. We also studied changes in gut microbiota induced by TMP-SMX. We used the non-compartment analysis to compare the pharmacokinetics of ATV in a parallel group of rats treated with a low or therapeutic dose of TMP-SMX for nine days to untreated control rats. Gut microbiota was characterized using qPCR and High Throughput Sequencing of 16S rDNA. Rats treated with TMP-SMX showed a much broader exposure to ATV compared to the control group (AUC0-8h (ng.mL-1.h), 25975.9±4048.7 versus 2587.6±546.9, p=0.001). The main observation regarding the gut microbiota was a lower proportion of enterobacteria related to the administration of TMP-SMX. Moreover, the Total Gastrointestinal Transit Time (TGTT) was longer in the TMP-SMX treated group. Concomitant administration of TMP-SMX and ATV significantly increased ATV exposure in rats. This increase could be the result of a prolonged TGTT leading to an increase in the intestinal residence time of ATV favoring its absorption. Gut microbiota changes induced by TMP-SMX could be at the origin of this prolonged TGTT. If demonstrated in humans, this potential interaction could be accompanied by an increase in the adverse effects of ATV.

Sections du résumé

BACKGROUND BACKGROUND
Cotrimoxazole (TMP-SMX) is concomitantly used as a primary prophylaxis of opportunistic infections with antiretroviral agents, such as Atazanavir (ATV). Results from an ex vivo study showed changes in intestinal absorption of ATV when rats were pretreated with TMP-SMX. The objective of this in vivo study is to determine the effect of TMP-SMX on the pharmacokinetics of ATV in rats. We also studied changes in gut microbiota induced by TMP-SMX.
METHODS METHODS
We used the non-compartment analysis to compare the pharmacokinetics of ATV in a parallel group of rats treated with a low or therapeutic dose of TMP-SMX for nine days to untreated control rats. Gut microbiota was characterized using qPCR and High Throughput Sequencing of 16S rDNA.
RESULTS RESULTS
Rats treated with TMP-SMX showed a much broader exposure to ATV compared to the control group (AUC0-8h (ng.mL-1.h), 25975.9±4048.7 versus 2587.6±546.9, p=0.001). The main observation regarding the gut microbiota was a lower proportion of enterobacteria related to the administration of TMP-SMX. Moreover, the Total Gastrointestinal Transit Time (TGTT) was longer in the TMP-SMX treated group.
CONCLUSION CONCLUSIONS
Concomitant administration of TMP-SMX and ATV significantly increased ATV exposure in rats. This increase could be the result of a prolonged TGTT leading to an increase in the intestinal residence time of ATV favoring its absorption. Gut microbiota changes induced by TMP-SMX could be at the origin of this prolonged TGTT. If demonstrated in humans, this potential interaction could be accompanied by an increase in the adverse effects of ATV.

Identifiants

pubmed: 31702484
pii: CDM-EPUB-101801
doi: 10.2174/1389200220666191023105609
doi:

Substances chimiques

Anti-Bacterial Agents 0
HIV Protease Inhibitors 0
Atazanavir Sulfate 4MT4VIE29P
Trimethoprim, Sulfamethoxazole Drug Combination 8064-90-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

898-906

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Joe Miantezila Basilua (JM)

EA4065 Intestinal Ecosystem, Probiotics, Antibiotics, Paris Descartes University SPC, Paris, France.
Clinical Pharmacology Unit, University of Kinshasa, Kinshasa, Democratic Republic of Congo.

Olivier Sawoo (O)

EA4065 Intestinal Ecosystem, Probiotics, Antibiotics, Paris Descartes University SPC, Paris, France.
Microbial Ecology Laboratory (MIEL), CNAM, F-75003 Paris, France.

Irène Mangin (I)

EA4065 Intestinal Ecosystem, Probiotics, Antibiotics, Paris Descartes University SPC, Paris, France.
Microbial Ecology Laboratory (MIEL), CNAM, F-75003 Paris, France.

Flore Dossou-Yovo (F)

EA4065 Intestinal Ecosystem, Probiotics, Antibiotics, Paris Descartes University SPC, Paris, France.
Microbial Ecology Laboratory (MIEL), CNAM, F-75003 Paris, France.

Aline Boussard (A)

UMR 1145 Food Process Engineering, AgroParisTech, INRA, Paris-Saclay University, Massy 91300, France.
CNAM, UMR1145 Food Process Engineering, Paris F-75003, France.

Lucie Chevillard (L)

UMR-S 1144 Therapeutic Optimization in Neuropsychopharmacology, Paris Descartes University, Paris, France.

Gaston T Lutete (GT)

Clinical Pharmacology Unit, University of Kinshasa, Kinshasa, Congo.

Bruno Eto (B)

TBC TransCell-Lab, Paris, France.

Gilles Peytavin (G)

IAME, UMR 1137, INSERM, Paris Diderot University, Sorbonne Paris Cité, Paris, France.
Pharmaco-Toxicology Laboratory, Bichat Hospital, Paris, France.

Philippe Pochart (P)

EA4065 Intestinal Ecosystem, Probiotics, Antibiotics, Paris Descartes University SPC, Paris, France.
Microbial Ecology Laboratory (MIEL), CNAM, F-75003 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH